Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives

Discovered in 2007, anaplastic lymphoma kinase (ALK) gene rearrangements positive (ALK+) lung cancers compose a small subset of non-small cell lung cancer (NSCLC), with rapidly expanded treatments. There are currently several ALK inhibitors, including crizotinib, ceritinib, alectinib, brigatinib, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Karachaliou, Niki, Fernandez Bruno, Manuel, Bracht, Jillian Wilhelmina Paulina, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580130/
https://www.ncbi.nlm.nih.gov/pubmed/31354290
http://dx.doi.org/10.2147/OTT.S174548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580130/
https://www.ncbi.nlm.nih.gov/pubmed/31354290
http://dx.doi.org/10.2147/OTT.S174548

Ejemplares similares